Breckenridge signs multiproduct agreement with Welding
The agreement currently covers one delayed-release tablet product and two injectable products, which collectively had sales of $300 million for the year ended April 2021.
Breckenridge has signed a multi-product agreement with Welding GmbH, under which Welding will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.
The agreement currently covers one delayed release tablet product and two injectable products. Of these three products, one ANDA has been submitted to the Food and Drug Administration, one ANDA is expected to be submitted to the FDA in July, and one ANDA is in an advanced stage of development.
The brand and generics of these three products had annual sales of $300 million during the 12 months ended April 2021, according to industry sales data.